Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient
NVX-CoV2601 was safe and immunogenic with similar humoral responses compared to healthy controls, making it a viable alternative for immunosuppressed patients.
Authors
- Amir Masoud Forati (ORCID: https://orcid.org/0000-0002-6461-5448)
- MARY S. HAYNEY
- Miranda R. Cai
- Ahamed Lazim Vattoth (ORCID: https://orcid.org/0009-0009-2570-8025)
- Raj Kalkeri (ORCID: https://orcid.org/0000-0002-1188-277X)
- Zhaohui Cai (ORCID: https://orcid.org/0000-0001-5935-3570)
- Sandesh Parajuli (ORCID: https://orcid.org/0000-0003-1667-7465)
- Brandy Warren
- Shane Cloney-Clark
- Mingzhu Zhu
- Freddy Caldera
Institutions
- University of Wisconsin–Madison (US)
- Novavax (United States) (US)
Publication Details
- Journal
- Vaccine
- Published
- 2026-01-16
- DOI
- https://doi.org/10.1016/j.vaccine.2026.128208
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00